NASDAQ:EIDX - Eidos Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.52 -1.32 (-4.74 %)
(As of 04/24/2019 10:36 AM ET)
Previous Close$27.84
Today's Range$25.90 - $28.0925
52-Week Range$8.89 - $29.74
Volume50,775 shs
Average Volume127,744 shs
Market Capitalization$976.44 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIDX
CUSIPN/A
CIKN/A
Phone415-887-1471

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-11,940,000.00

Miscellaneous

Employees11
Market Cap$976.44 million
Next Earnings Date7/15/2019 (Estimated)
OptionableNot Optionable

Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics Inc (NASDAQ:EIDX) issued its earnings results on Monday, April, 15th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. View Eidos Therapeutics' Earnings History.

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, July 15th 2019. View Earnings Estimates for Eidos Therapeutics.

What price target have analysts set for EIDX?

7 brokers have issued 1-year price objectives for Eidos Therapeutics' stock. Their forecasts range from $13.00 to $38.00. On average, they expect Eidos Therapeutics' stock price to reach $28.5714 in the next twelve months. This suggests a possible upside of 7.7% from the stock's current price. View Analyst Price Targets for Eidos Therapeutics.

What is the consensus analysts' recommendation for Eidos Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eidos Therapeutics.

Has Eidos Therapeutics been receiving favorable news coverage?

Media headlines about EIDX stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eidos Therapeutics earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the near term.

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Micron Technology (MU), Exelixis (EXEL), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Alibaba Group (BABA), Roku (ROKU), Pfizer (PFE), bluebird bio (BLUE), Celgene (CELG) and DexCom (DXCM).

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the folowing people:
  • Dr. Neil Kumar, CEO & Director (Age 40)
  • Dr. Jonathan C. Fox FACC, M.D., Ph.D., Pres & Chief Medical Officer (Age 62)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Hoyoung Huh, Consultant (Age 50)
  • Ms. Christine E. Siu, Chief Financial Officer (Age 42)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $26.52.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $976.44 million. The company earns $-11,940,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Eidos Therapeutics employs 11 workers across the globe.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is http://www.eidostx.com.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]


MarketBeat Community Rating for Eidos Therapeutics (NASDAQ EIDX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  118
MarketBeat's community ratings are surveys of what our community members think about Eidos Therapeutics and other stocks. Vote "Outperform" if you believe EIDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel